首页 | 本学科首页   官方微博 | 高级检索  
检索        

罗格列酮对果糖饲养的肾性高血压大鼠糖、脂代谢的影响
引用本文:凌宏艳,文金生,周寿红,龙光,李良,胡弼.罗格列酮对果糖饲养的肾性高血压大鼠糖、脂代谢的影响[J].中国动脉硬化杂志,2003,11(6):520-522.
作者姓名:凌宏艳  文金生  周寿红  龙光  李良  胡弼
作者单位:南华大学医学院生理学教研室,湖南省衡阳市,421001
基金项目:湖南省教育厅科研项目 ( 0 1C189)资助
摘    要:为探讨X综合症大鼠糖、脂代谢的变化以及罗格列酮的干预作用 ,采用高果糖饲养两肾一夹SD大鼠建立典型的X综合症模型 ,观察罗格列酮对其糖、脂代谢的影响。实验分用药组 罗格列酮 5mg (kg·d)干预 ]、未用药组 (X综合症模型 )和假手术组 ,分别测定各组术后 8周和 11周的收缩压及血脂、血糖和血胰岛素水平 ,同时计算胰岛素敏感指数。结果发现 ,8周时用药组和未用药组收缩压、甘油三酯、总胆固醇、低密度脂蛋白胆固醇、空腹血糖及血浆胰岛素水平与假手术组相比显著升高 ,胰岛素敏感指数、高密度脂蛋白胆固醇则明显降低。 11周时用药组收缩压、甘油三酯、空腹血糖及血清胰岛素水平与 8周时比较显著降低 ,总胆固醇、高密度脂蛋白胆固醇和胰岛素敏感指数显著升高 ,低密度脂蛋白胆固醇升高但没有显著性意义 ;而另两组 11周时与 8周时比较变化不明显。结果提示 ,罗格列酮能降低X综合症大鼠的血压 ,减轻胰岛素抵抗 ,纠正糖、脂代谢紊乱。

关 键 词:罗格列酮  高血压  大鼠  葡萄糖氧化酶法  血糖  血脂  胰岛索
文章编号:1007-3949(2003)11-06-0520-03
收稿时间:2003/5/6 0:00:00
修稿时间:2003年5月6日

The Effects of Rosiglitazone on Sugar and Lipid Metabolism in Fructose-Fed Renal Hypertensive Rats
LING Hong-Yan,WEN Jing-Sheng,ZHOU Shou-Hong,LONG Guang,LI Liang,and HU Bi.The Effects of Rosiglitazone on Sugar and Lipid Metabolism in Fructose-Fed Renal Hypertensive Rats[J].Chinese Journal of Arteriosclerosis,2003,11(6):520-522.
Authors:LING Hong-Yan  WEN Jing-Sheng  ZHOU Shou-Hong  LONG Guang  LI Liang  and HU Bi
Institution:Department of Physiology, NanHua University, Hengyang 421001, China
Abstract:Aim To investigate the changes of sugar and lipid metabolism in syndrome X rats and examine the intervenient effects of rosiglitazone on them. Methods Syndrome X was produced by two-kindey, one-cliped (2K1C) rats fed with high fructose. Systolic blood pressure (SBP), blood lipid, the level of blood sugar and serum insulin were measured respectively in groups, and insulin sensitive index (ISI) was also calculated. Results At 8 weeks, compared with sham operation group, SBP, triglyceride (TG), blood total cholesterol (TC), low density lipoprotein cholesterol (LDLC), fasting blood sugar (FBS), fasting serum insulin (FSI) significantly increased; insulin sensitive index (ISI), high density lipoprotein cholesterol (HDLC) significantly reduced in groups with or without rosiglitazone treatment. At 11 weeks, in the group with rosiglitazone treatment, TG, FBS and FSI remarkably reduced, TC, HDLC and ISI significantly elevated, but LDLC only slightly increased; While other two groups did not change significantly compared with that at 8 weeks. Conclusions Rosiglitazone can reduce BP, improve insulin resistance and correct the abnormity of sugar and lipid metabolism.
Keywords:Renal Hypertension  Blood Sugar  Blood Lipid  Rosiglitazone  Syndrome X  Rats
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中国动脉硬化杂志》浏览原始摘要信息
点击此处可从《中国动脉硬化杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号